Kornimate/medical-research-clean huggingface dataset:
one-hour troponin in a low-prevalence population of acute coronary syndrome

Conditions: Non-ST Elevation Myocardial Infarction; Acute Coronary Syndrome; Angina, Unstable; NSTEMI - Non-ST Segment Elevation MI

Summary: this study aims to evaluate if the 1-hour rule-in/rule-out algorithm for a high-sensitivity cardiac troponin t (hs-ctnt) is safe and effective for use in the primary care where the patients have a lower pretest probability of an acute myocardial infarction (mi). during this study troponins will be collected at 0-, 1- and 4/6-hours, where absolute changes in the values will decide whether the patient need hospitalization or not.

many patients seek oslo accident and emergency outpatient clinic (oaeoc) with chest pain. the majority of these patients have symptoms suggestive of a benign non-cardiac chest pain. these patients do not need a directly transfer to the hospital, but can be admitted to the observation unit at the oaeoc for further pre-hospital testing, including serial troponins for a safe rule-out of acute mi. the main goal of this study is to improve the current routine at the observation unit at oaeoc by introducing the 1-hour algorithm for hs-ctnt for a faster rule-in/rule-out of acute mi. all recruited patients will have serial troponins drawn at 0, 1- and 4/6 hours, with the main hypothesis that the absolute changes within 1 hour can be used as surrogates for the changes and conclusions drawn after 4/6 hours. the cut-off levels used within the 0/1-hour algorithm are assay specific as specified in the 2015 european society of cardiology guidelines for the management of acute nstemi.

Eligibility criteria:
inclusion criteria: * patients at the outpatient clinic with suspected non-cardiac chest pain/symptoms who need further testing for a safe rule-out of an acute mi * written informed consent exclusion criteria: * acute stemi (st-elevation myocardial infarction) (directly to the hospital) * strong suspicion of an acute nstemi/unstable angina (directly to the hospital) * terminal kidney disease with a glomerular filtration rate (gfr) \< 30 * unable to communicate in norwegian, swedish, danish or english language

Keywords: acute mi acute myocardial infarction cardiac troponin high-sensitivity cardiac troponin t 0/1-hour algorithm outpatient clinic cardiac troponin chest pain
the study of pegylated liposomal doxorubicin contrast epirubicin for the treatment of diffuse large b-cell lymphoma

Conditions: Diffuse Large B-cell Lymphoma

Summary: 270 untreated patients, age between 18 and 65 years , with diffuse large b-cell lymphoma (b-dlcl) were treated with a pegylated liposomal doxorubicin (pl-doxorubicin) modiﬁed chop-rituximab regimen. pl-doxorubicin 35-40 mg/m(2)and epirubicin 70mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to chop-r regimen) every 21 days for six courses.

pl-doxorubicin 35-40 mg/m(2) and epirubicin 70mg/m(2) were given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to chop regimen) every 21days for six courses. the choice to adopt the dosage of 30 mg/m2(instead of 50 mg/m2 of conventionaldoxorubicin) was based on pharmacokinetic data and on the results of previous studies in lymphoma.rituximab 375 mg/m2 was given on day 0 in subsequent courses of therapy. granulocyte colony-stimulating factor was given in the presence of grade 4 neutropenia or febrile neutropenia until hematological recovery. treatment was stopped if lymphoma progressed, the patient refused further participation,or if there was any other intercurrent clinical condition or adverse event.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * diagnosis of previously-untreated dlbcl(patients with a transformed untreated low-grade lymphoproliferative disease were accepted) * ecog performance status \< 3 (and higher if due to lym-phoma) * no symptomatic cardiac arrythmias or heart failure * acceptable renal, hepatic and pulmonary function * standard laboratory and radiological staging procedures and left ventricular ejection fraction analysis by echocardiography or scintigraphy were required before therapy in all cases * the protocol was approved by the ethics review committee of each partici- pating center * all patients gave informed written consent. exclusion criteria: * patients with a previous history of cardiac disease; * hiv-hbsag-hcv positivity, central nervous system involvement or any other major clinicalcondition; * other than lymphoma, which might have precluded a regular therapeutic course, were excluded from the study.
a pilot study comparing two rehabilitation approaches for individuals with irritable shoulder pain

Conditions: Shoulder Pain

Summary: this pilot study will assess feasibility and obtain preliminary effects of a tissue based intervention to a biopsychosocial intervention in individuals with shoulder pain.


Eligibility criteria:
inclusion criteria: * shoulder pain intensity rated as 3/10 or higher in the past 24 hours exclusion criteria: * non-english speaking * systemic medical conditions that affect sensation, such as uncontrolled diabetes * history of shoulder surgery or fracture within the past 6 months * blood clotting disorder, such as hemophilia * contraindication to the application of ice ((blood pressure \> 140/90 mmhg, cold urticaria, cryogobulinemia, paroxysmal cold hemoglobinuria, circulatory compromise) * unable to exercise without a medical clearance (assessed on the par-q+ on the first visit) * exceed pressure and sensory safety thresholds (assessed on the first visit) * categorized as low irritability (assessed on the first visit) * currently pregnant * currently receiving physical therapy to treat shoulder pain
cholecystectomy after successful endoscopic common bile duct stone extraction in elderly

Conditions: Cholecystectomy, Laparoscopic; Choledocholithiasis; Cholelithiasis

Summary: the goal of this study is to compare safety and efficacy of laparoscopic cholecystectomy versus wait-and-see policy after endoscopic removal of common bile duct stones in elderly. the primary endpoint is a composite outcome: death or major postoperative complications or recurrent biliary disease within 1 year after randomization.

elderly patients with common bile duct stones are asked to participate this randomized trial after successful endoscopic removal of common bile duct stones. the hypothesis of the study is that wait-and-see policy is non-inferior to laparoscopic cholecystectomy. four hundred patients are randomized 1:1 to either laparoscopic cholecystectomy group or wait-and see group. cholecystectomy is done on the same admission or within two weeks after randomization. one interim analysis is planned for the trial after 100 randomized patients to assess safety. the trial is terminated if there is a statistically significant difference in primary outcome with p\<0.001 (chi-square test) between the study arms.

Eligibility criteria:
inclusion criteria: * common bile duct stones cleared after endoscopic retrograde cholangio pancreatography (ercp) * age \>= 80 years or age 75-79 years with a charlson comorbidity index \>=2 * gallbladder in situ exclusion criteria: * acute cholecystitis * biliary pancreatitis * severe or moderately severe post-ercp pancreatitis * chronic pancreatitis * bile duct pathology * widespread malignancy * unable to give consent
efficiency evaluation of intradiploic intra-osseus anesthesia versus inferior alveolar nerve block

Conditions: Dental Pain

Summary: management of dental pain emergencies is a challenge for the clinician, particularly when pain is due to endodontic infection. tested hypothesis is intradiploic anesthesia is more effective and quicker than inferior alveolar nerve block for mandibular molars anesthesia. the aim of the study is the evaluation of quicksleeper efficiency used in first intention versus inferior alveolar nerve block used in most current dental treatment.

management of dental pain emergencies is a challenge for the clinician, particularly when pain is due to endodontic infection. failure rate of local anesthesia highly increases with irreversible pulpitis or inflamed periradicular tissue. tested hypothesis is intradiploic anesthesia is more effective and quicker than inferior alveolar nerve block for mandibular molars anesthesia (from teeth 35 up to 38 and from 45 up to 48). the primary aim of the study is the evaluation of quicksleeper efficiency used in first intention versus inferior alveolar nerve block used in most current dental treatment. four clinical situations are evaluated : pulpitis; periapical abcess; pulpal hyperemia; asymptomatic decayed tooth. evaluated parameters are : speed of sedation, ability of cure, additional anesthesia needed, total of needles and cartridges used, side effects. time and validation of complete anesthesia is controlled by pulp tester. studied population is patients cared in restorative, endodontics department. pulpal and periapical molar and premolar sedation is randomly managed by inferior alveolar nerve block or quicksleeper intraosseous anesthesia, among studied population (divided in 2 groups of 50 patients). pulp-tester measures anesthesia minute by minute. the comparison of study results to bibliography, guidelines and advantages for using mechanical quicksleeper anesthesia system will be discussed.

Eligibility criteria:
inclusion criteria: * irreversible pulpitis on second mandibular premolar or mandibular molars * necessity of pulpotomy or pulpectomy exclusion criteria: * pregnancy, chest feeding * non dental emergency state * hypersensibility to local anesthesia * pheochromocytoma * irregularity of cardiac rhythm * myocardial infarct in the 6 previous months * hepatic porphyria

Keywords: restorative odontology patients cared in restorative odontology department
stress reactivity of physical stressor on depression

Conditions: Depression

Summary: depressive elderly individuals have showed higher basal level of cortisol and lower level of dehydroepiandrosterone (dhea). moreover, changes on these hormone levels have also observed in reactivity of an acute stress, such as physical exercise. on the other hand, physical training can modulate the release of these hormones. therefore, depressive elderly individuals physically actives might show attenuated reactivity of an acute physical stressor compared to sedentary elderly individuals. the aim of these study is to compare the effect of an acute physical stressor on cortisol levels in depressive and healthy individuals, physically actives and sedentaries. additionally, the sulfated form of dhea (dheas) serves as a reservoir for dhea, because of that it is expected that dheas levels might reduce after the acute physical exercise.

depressive and healthy individuals were submitted to one session of 30 minutes of physical exercise of moderate intensity. before and soon after the exercise it was collected saliva - to analyse cortisol and dheas hormones - and some psychological and physical aspects were also collected, such as anamneses, scales of anxiety, temperaments, mood, stress and quality of life. moreover, during exercise heart rate and mood scale were assessed. to evaluate the reactivity and recovery of physical stressor (physical exercise) saliva tubes and psychological scales were collected 30 minutes and 45 minutes after the end of exercise.

Eligibility criteria:
inclusion criteria: * age above of 60 years old * clinical diagnostic of depression exclusion criteria: * hormonal replacement * physical disease * fasting

Keywords: depression physical exercise stress
allogenic stem cell transplantation for children, adolescents and young adults with relapsed or refractory aml

Conditions: Acute Myeloid Leukemia (AML)

Summary: 1. to evaluate whether stem cell transplantation from a matched sibling donor is equivalent to a matched unrelated donor in in a second complete remission of acute myeloid leukemia (aml). 2. to evaluate whether stem cell transplantation (sct) after chemotherapy (flamsa-schema) increases survival compared to a threshold derived from historical data 3. to evaluate whether sct from haploidentical donors for children having no matched donor will result in better survival with acceptable toxicity.

target variables: * treatment response * event free survival * leukemia free survival * graft versus host disease * regimen related toxicity

Eligibility criteria:
inclusion criteria: * aged between 0-21 years * patients suffering from either refractory de novo aml or relapsed aml or patients with very high risk aml in cr1 * in sexually active patients two reliable contraception methods are used. this includes every combination of a hormonal contraceptive (such as injection, transdermal patch, implant, cervical ring) or of an intrauterine device(iud) with a barrier method (e.g. diaphragm, cervical cap, or condom) or with a spermicide. * written informed consent of patient, parents or legal guardians exclusion criteria: * severe renal impairment (gfr \< 30% predicted for age) * pregnant or lactating females * current participation in another clinical trial * patients ≥ 12 years old for group 1 ("bucymel") (patients younger that 12 years continue to be included)

Keywords: relapsed or refractory aml in children, adolescents and young adults
to study generic calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064%, in the treatment of scalp psoriasis

Conditions: Scalp Psoriasis

Summary: this is a phase iii, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064% of glenmark pharmaceuticals ltd to that of the marketed product taclonex® topical suspension of leo pharma inc. in the treatment of scalp psoriasis.


Eligibility criteria:
inclusion criteria: 1. male or non-pregnant, non-lactating female subjects aged at least 18 years at visit 1. 2. a clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least 10% of the scalp and clinical signs of psoriasis vulgaris on trunk and/or limbs. 3. a pga of disease severity of the scalp psoriasis consistent with at least moderate disease severity (grade ≥ 3). 4. a plaque elevation of at least moderate severity (grade ≥ 3) at the scalp target lesion site. the most severe scalp lesion at baseline should be identified as the target lesion. exclusion criteria: 1. current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative, or pustular psoriasis. 2. other inflammatory skin disease in the scalp that may confound the evaluation of the scalp psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea capitis). 3. presence of pigmentation, extensive scarring, pigmented lesions, or sunburn in the scalp that could interfere with the rating of efficacy parameters. 4. presence of viral lesions, fungal, bacterial, or parasitic infections and/or atrophic (thinning) skin on the scalp. 5. history of psoriasis unresponsive to topical treatments. 6. subjects with planned phototherapy and/or exposure to ultraviolet a (uva) and/or uvb during the study.
a retrospective cohort study on the risk of serious infections in rheumatoid arthritis patients receiving tocilizumab

Conditions: Infection; Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate whether the risk of serious infections in rheumatoid arthritis patients with tocilizumab is higher than in those with tumor necrosis factor inhibitors using the nationwide real-world data.

this observational, retrospective cohort study using the korean national health insurance (nhi) data will evaluate whether the risk of serious infections (sis) in rheumatoid arthritis patients treated with tocilizumab is higher than in those with tumor necrosis factor inhibitors. we will compare incidence rates between two groups and estimate relative risks of sis in tocilizumab users using the time-dependent cox proportional hazard regression. various covariates potentially related to ra severity and occurrence of infection will be assessed and used for adjustment.

Eligibility criteria:
inclusion criteria: * individuals who had a diagnosis of rheumatoid arthritis (icd-10 codes: m05-06) between 2013 and 2018 exclusion criteria: * individuals less than 18 years of age * having no records of prescription of tocilizumab or tnfi at least once between 2013 and 2018

Keywords: tocilizumab serious infection rheumatoid arthritis tumor necrosis factor inhibitors
hiv prevention program for african american teen males

Conditions: HIV Infections; Sexually Transmitted Infections

Summary: the purpose of this study is to test if sexual health interventions can reduce the incidence of stis among african american teens (15 to 21 years old). by doing this study, we hope to help african american teens improve their condom use skills and encourage them to use condoms more frequently. if the number of stis in this population can be decreased, the health of african american teen males will greatly improve. we also believe that sexual partners (typically african american teen females) will also benefit.

based on the observation that african americans are vastly more likely than their white and hispanic counterparts to be infected by the human immunodeficiency virus (hiv), the centers for disease control and prevention (cdc) has termed aids a "health crisis" for african americans and has called for a heightened national response to this glaring racial disparity. the crisis is especially dramatic in the southern united states. thus, the search for effective interventions tailored to this population is a national priority. this study expands upon a previous study conducted among young african american men. in the previous study we developed and tested the efficacy of a brief, clinic-based, program designed to interactively promote safer sex for african american men (18 to 29 years of age) engaging in sex with women. adjusted findings from the previous study provided relatively robust support for program efficacy, with men who received the intervention program being about two-thirds less likely, than controls, to acquire an sti during a 6-month period. this study expands on the work performed in the previous study by developing and testing a version for younger african american males (i.e., teen males). the purpose of this study is to test the efficacy of a brief, clinic-based and theory-guided, intervention designed to reduce sti incidence among african american teen (15 to 20 years old) males presenting themselves for sti testing.

Eligibility criteria:
inclusion criteria: * at least 15, but not more than 23 years of age * attending the clinic for the expressed purpose of being tested for sexually transmitted infections * engaging in penetrative sex (penile-vaginal or penile-anal) at least once in the past 2 months * willingness to return for the two planned follow-up assessments exclusion criteria: * self-report of being hiv positive

Keywords: african american men condoms randomization brief intervention hiv hiv seronegativity
predictive values of presepsin levels in ascites in patients with chronic liver failure

Conditions: Ascites Hepatic; Liver Failure; Cirrhosis, Liver

Summary: the investigators aim to study the predictive value of presepsin in ascites in newly admitted patients with chronic liver failure.

presepsin is a plasmatic cleaved fragment of cd14. cd14 is a toll like receptor who has the role to identify certain lipopolysaccharides on the surface of bacteria (aerobes and anaerobes), thus promoting an inflammatory response. a study of 153 patients with liver cirrhosis published by a team of investigators from iasi, romania, has proven an useful role of plasma presepsin in early diagnosis of infections in patients in acute on chronic liver failure. in addition, plasma presepsin has been proposed as an independent predictor of mortality in patients with decompensated liver cirrhosis, without concomitant bacterial infections. question to be answered by this study the investigators aim to evaluate the predictive role of ascites presepsin in patients with chronic liver failure. hypothesis presepsin levels in ascites may have a prognostic role in patients with ascites and chronic liver failure.

Eligibility criteria:
inclusion criteria: * patient with ascites and chronic liver failure * no contraindications and technical possibility to perform diagnostic paracentesis * age above 18 years old * informed consent exclusion criteria: * contraindications to paracentesis or technical impossibility to perform paracentesis * absence of informed consent
il2 imaging in renal transplantation

Conditions: Kidney Transplant Rejection

Summary: after renal transplantation 5 to 10% of patients experience allograft rejection. rapid and accurate diagnosis is vital for implementation of additional immunosuppressive therapy. currently, a renal biopsy is essential for the diagnosis of renal allograft rejection. however, this is an intervention associated with complications like bleeding, patient discomfort and hospital admission. additionally, limited biopsy sample size may lead to false negative results. so, the introduction of a new non-invasive diagnostic tool for allograft rejection could have major implications for the care of renal transplant recipients. for the purpose of visualizing infiltrating t lymphocytes with positron emission tomography (pet), the tracer 18-fluor-interleukin-2 (\[18f\]fb-il2) has been developed. the investigators hypothesized that a high correlation exists between \[18f\]fb-il2 uptake and the extend of t cell infiltration into renal transplants with signs of rejection


Eligibility criteria:
inclusion criteria: * female or male aged between 18 and 80 years. * renal transplant recipients * the patient understands the purpose and risks of the study and has given written informed consent to participate in the study. * all patients will have a clinical indication for renal biopsy. exclusion criteria: * patients with multiple-organ transplants. * female patients who are pregnant or unwilling to use adequate contraception during the study. * claustrophobia * altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent. * a clinical reason for an immediate start of a therapeutic intervention with immunosuppressive medication.
an 8-week refractory chronic cough study (mk-7264-021)

Conditions: Refractory Chronic Cough

Summary: this was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (af-219) in participants with refractory chronic cough.


Eligibility criteria:
inclusion criteria: * women and men between 18 and 80 years of age inclusive * have refractory chronic cough * women of child-bearing potential must use 2 forms of acceptable birth control * have provided written informed consent. * are willing and able to comply with all aspects of the protocol. exclusion criteria: * current smoker * forced expiratory volume (fev1)/forced vital capacity (fvc) \< 60% * history of upper respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the baseline * history of opioid use within 1 week of the baseline visit * body mass index (bmi) \<18 kg/m2 or ≥ 40 kg/m2 * history of concurrent malignancy or recurrence of malignancy within 2 years prior to screening (not including participants with \<3 excised basal cell carcinomas) * screening systolic blood pressure (sbp) \>160 mm hg or a diastolic blood pressure (dbp) \>90 mm hg * significantly abnormal laboratory tests at screening * clinically significant abnormal electrocardiogram (ecg) * pregnant or breastfeeding * other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator or sponsor, would make the participants inappropriate for entry into this trial